anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Reduced propulsion of the paretic leg contributes to impaired walking in people poststroke. The goal of this study was to determine whether phasic electrical stimulation to the paretic gastrocnemius muscle combined with resistance applied to the nonparetic leg during swing phase while walking would enhance muscle activation of the paretic gastrocnemius and propulsive force of the paretic leg. Fifteen individuals who had a stroke visited the lab once to complete two experimental sessions (i.e., crossover design; session order randomized). Each session consisted of 1) treadmill walking with either "motor stimulation and swing resistance" or "swing resistance only" (10-min walking: 1-min baseline, 7-min adaptation to intervention, and 2-min postadaptation) and 2) instrumented treadmill walking before and after treadmill walking. Participants showed enhanced muscle activation of the paretic gastrocnemius (P = 0.03) and improved anteroposterior ground reaction force of the paretic leg (P = 0.01) immediately after the treadmill walking with "motor stimulation and swing resistance," whereas no improvements after the walking with "swing resistance only." Those enhanced gastrocnemius muscle activation (P = 0.02) and improved ground reaction force (P = 0.03) were retained until the late postadaptation period and 10 min after treadmill walking, respectively. Walking with "motor stimulation and swing resistance" may enhance forced use of the paretic leg and improve propulsive force of the paretic leg. Applying phasic electrical stimulation to the paretic gastrocnemius muscle and swing resistance to the nonparetic leg during walking can be used as a novel intervention strategy to improve motor control of the paretic leg and walking in people poststroke.NEW & NOTEWORTHY Applying targeted motor stimulation to the paretic calf muscle and swing resistance to the nonparetic leg during walking induced significant enhancement in muscle activation of the paretic gastrocnemius and anterior-posterior ground reaction force of the paretic leg, whereas no enhancements were observed after walking with swing resistance only. Furthermore, the enhanced gastrocnemius muscle activation and ground reaction force of the paretic leg were partially retained at the late postadaptation period and 10 min after treadmill walking.
The invention provides a method for continuously optimizing outpatient service by combining patient demand investigation with PDCA (digital versatile disc) circulation management. The method is performed by a four-stage loop: planning, executing, checking and acting to achieve continuous optimization of the outpatient service flow. First, during the planning phase, data collection and analysis, including patient demand surveys, are performed to identify points of improvement and to formulate an implementation plan. And secondly, in the execution stage, specific measures such as appointment management system optimization, medical personnel scheduling adjustment, electronic health record system introduction and the like are implemented. Then, in the inspection stage, data is collected and evaluated to evaluate the improvement effect. Finally, in the action stage, effective measures are standardized and the practice of not reaching standards is regulated. The method is outstanding and innovative in that the PDCA management cycle, the data-driven decision process, the dynamic response and the flexible adjustment are combined, and the cross-department collaboration and the continuous improvement culture are combined, so that a brand new continuous optimization scheme is provided for the outpatient service.
PURPOSE:To provide a remedy for hepatopathy containing the extract of wild grape, exhibiting remarkable ameliorating effect against hepatocytic disorder caused by carbon tetrachloride, etc., and complement-mediated hepatocytic disorder and having low toxicity. CONSTITUTION:A root of wild grape is crushed to proper size, immersed in 5-10 times volume (V/W) of methanol, leached by leaving standing for 3-4 days at room temperature and concentrated under reduced pressure to obtain an extract. The similar operation is repeated twice and the obtained extracts are united together and partitioned with 10-15 (V/W) (based on the extract) of a mixture of ethyl acetate and water. The ethyl acetate layer is separated, the aqueous layer is added with the same amount of ethyl acetate and the extraction procedure is repeated twice. The obtained extracts are united to the above ethyl acetate extract and the solvent is distilled off under reduced pressure to obtain an extract of the root of wild grape. The extract contains resveratrol of formula I, epsilon-viniferin of formula II, epicatechin of formula III and novel compounds of formula IV-formula VI as active components exhibiting remedying effect against hepatopathy.
During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
Patients undergo standard care microwave ablation or wedge resection followed by contrast-enhanced CT imaging at 1, 6, 12, 18 and 24 months. Patients also complete questionnaires over 10-15 minutes at baseline up to 9 months.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia in chronic kidney disease (CKD). Single ascending dose (SAD) and multiple ascending dose (MAD) studies assessed pharmacokinetics (PK), pharmacodynamics (PD), and safety of vadadustat in healthy volunteers. A single-dose, open-label study was conducted in patients with CKD stages 3 and 4 not on dialysis. In the SAD study, 48 healthy adult men (n = 8/cohort) received single doses of vadadustat (80-1,200 mg) or placebo. In the MAD study, 34 healthy adult men (n = 8-9/cohort) received daily vadadustat (500-900 mg) or placebo for 10 days. In the single-dose CKD study, 22 male and female patients with CKD (stage 3: n = 10; stage 4: n = 12) received single doses of vadadustat (500 mg). PK parameters included plasma vadadustat; PD biomarkers were measured, including erythropoietin (EPO) levels, reticulocytes, and others. Plasma vadadustat peaked 3-4 hours after single or multiple dosing in healthy volunteers, with a mean t 1/2 of approximately 4.5 hours. In patients with CKD, plasma vadadustat peaked at 5-6 hours, with a mean t 1/2 of 7.2 (stage 3) and 8.5 (stage 4) hours. Vadadustat AUC∞ and C max increased dose proportionally in SAD and MAD trials. In all trials, EPO concentrations increased in a dose-related manner and returned approximately to baseline by 24 hours. Adverse events were mild and considered not study drug related. The PK and PD results of these studies were utilized for further clinical development of vadadustat for treatment of anemia in CKD patients.
Although there are many sleep-related complaints in chronic obstructive pulmonary disease (COPD) patients, nocturnal leg cramps have not been adequately and extensively studied. This study fills a significant gap in the literature by determining the prevalence and influencing factors of nocturnal leg cramps in COPD patients. However, our findings also underscore the need for further research, inspiring future studies and interventions in this area. This study was conducted with a rigorous methodology, employing a comprehensive approach to evaluate the probability of experiencing nocturnal leg cramps in 215 COPD and 215 control group patients matched for age and gender. Logistic regression analysis was used, supplemented by artificial neural networks, to identify the influencing factors. This robust methodology ensures the reliability and validity of our findings. The findings of this study are not only significant but also enlightening, shedding light on the prevalence and influencing factors of nocturnal leg cramps in COPD patients. The frequency of experiencing these cramps was found to be 40.9% in chronic obstructive pulmonary patients and 21.9% in the control group (p < .05). In COPD patients, factors such as milk group food consumption, blood erythrocyte level, the cover used while sleeping, blood creatinine level, the presence of coronary artery disease, the diagnosis of diabetes mellitus, the upper mid-arm muscle area, and use of drugs with methylxanthine active ingredient methylxanthine were found to affect the occurrence of these cramps. Our findings not only call for further research but also have immediate practical implications. They highlight the crucial role of nurses in managing nocturnal leg cramps in COPD patients. By controlling patients' cold stress, the bed covers they use, and their dairy product consumption, nurses can significantly contribute to managing these cramps, thereby improving the quality of life for these patients. This underscores the importance of their role in patient care and management.
The study consists of 9 visits. Duplimab will used in the treatment of adult onset atopic dermatitis. Qualified subjects will receive 5 dupilumab open-label injections. Skin biopsies/ skin strips will be obtained at the beginning and the end of treatment. TARC and IgE levels will be obtained at the beginning and end of treatment. Subjects will complete daily diaries assessing atopic dermatitis symptoms. Patient reported out comes will be completed at each visit
BACKGROUND: There is a great deal of confusion associated with conversion from CII opioid to buprenorphine products. The data presented supports that patients can be converted from high dose opioid medication to buprenorphine products safely and effectively. This presentation will provide a road map to help guide practitioners who are interested in applying this to their clinical practice.
PURPOSE/HYPOTHESIS: Thepurposeoftheresearchwasnotonlytodiscoverifconversiontoapartialagonist CIII medication from full agonist CII medications would be achieveable without sacrificing analgesia, but also to provide guidance to providerswhoareinterestedinpursuingthisoptioninclinicalpractice. Procedures/data/observations: Patients who met inclusion criteria were stratified into subgroups on the basis of pre- conversion morphine milligram equivalents, whether they remained on opioids for breakthrough pain postconversion, and pre- and postconversion numerical rating scale pain scores. Outcomes of interest included the differences between pre- and postconversion numerical rating scale pain scores and daily morphine milligram equivalents for each sub-group. Of 157 patients reviewed, 87.9% were successfully converted to buprenor-phine buccal film. Overall, numericalrating scale pain scores were stable after conversion. Statistically significant reductions were demonstrated in the <90 daily morphine milligram equivalent subgroup. Postconversion daily morphine milligram equivalents decreased by 85.4% from baseline. Change in daily morphine milligram equivalents is representative of patients who remained on breakthrough pain medication.
CONCLUSIONS/APPLICATIONS: Results demonstrate continued analgesia after conversion to buprenorphine buccal film despite reductions in daily morphine milligram equivalents. Most patients were able to convert directly from their long-acting opioid to buprenorphine buccal film and stabilized without the use of concomitant opioids for breakthrough pain. Aggressive titration strategies were associated with greater success. This data proves that conversion from full agonist CII medications is possible without sacrificing analgesia while reducing the risk of adverse events associated with full agonist CII medications.
NEW MATERIAL:A 4-imidazolin-2-one derivative shown by the formula I [R<1> is H, lower alkyl, cyclo lower alkyl, lower alkenyl, halo(lower)alkyl, etc.; r<2> is H, or lower alkyl; group shown by the formula II and neighboring benzene are bonded to form heterocylic benzothiazolinyl, benzoxazolinyl group, 1,4- benzoxazinyl, qunolyl, etc., and the heterocyclic group may be hydrogenated) and its salt. EXAMPLE:1,4-Dimethyl-5-(3-methyl-2-oxobenzoxazolin-5-yl)-4-imidazolin- 2-one. USE:Having cardiac action, useful for remedying heart diseases such as cardiac incompetence, etc. Being administered orally or parenterally or through external use. PREPARATION:For example, as shown by the reaction formula, a compound shown by the formula III is reacted with a substituted isocyanate shown by the formula IV, to give a compound shown by the formula I.
PURPOSE:To obtain a preventive and treating agent for ischemic encephalic disorders, containing selenious acid or pharmaceutically permissible salt thereof and capable of suppressing the disorders of neurocytes caused by glutamic acid. CONSTITUTION:An agent for suppressing necrosis of neurocytes containing selenious acid or pharmaceutically permissible salt (e.g. Na salt, L salt, K salt, Ca salt, Mg salt, etc.) as an active ingredient and capable of suppressing the disorders of neurocytes caused by glutamic acid. Prevention and treatment of ischemic encephalic disorders are made possible by using the above-mentioned agent. The agent can be safely administered to patients in a form of tablet, capsule, pill, inhalant, liquid, injection, drops or suppository. In a case of oral administration, the agent is preferably used at an amount of about 0.5-50mg/adult/day.
FIELD: medicine, cosmetics. SUBSTANCE: method involves preparing a base, saline solution and its mixing with a base and natural biologically active additions. An agent has additionally buffer components to maintain pH at the range 7.5-11.0. Saline solution before its addition to a base is subjected for electrochemical treatment in diaphragm electrolyzer for 5-20 min. For preparing a cosmetic agent a part of an activated saline solution exhibiting a negative redox-potential from -200 to -700 mV is used at the following quantitative ratio of components, wt.-%: activated part of saline solution exhibiting a negative redox-potential from -200 to -700 mV with buffer components to maintain pH at the range 7.5-11.0 3.0-99.0, and a base or a base with natural biologically active additions - the rest. Saline solution is a 0.7-1.0% solution of NaCl or KCl, or CaCl 2 , or MgSO 4 , or their mixture at ratio 34:2:1:1, respectively, or ZnSO 4 . EFFECT: high nutrient, regenerating and antiseptic properties of a cosmetic agent, improved method of preparing. 3 cl, 1 tbl, 16 ex
BACKGROUND: Pulmonary fibrosis (PF) is an aging-related progressive lung disorder. The aged lung undergoes functional and structural changes termed immunosenescence and inflammaging, which facilitate the occurrence of fibrosis. Interleukin-10 (IL-10) is a potent anti-inflammatory and immunoregulatory cytokine, yet it remains unclear how IL-10 deficiency-induced immunosenescence participates in the development of PF.
METHODS: Firstly we evaluated the susceptibility to fibrosis and IL-10 expression in aged mice. Then 13-month-old wild-type (WT) and IL-10 knockout (KO) mice were subjected to bleomycin(BLM) and analyzed senescence-related markers by PCR, western blot and immunohistochemistry staining of p16, p21, p53, as well as DHE and SA-β-gal staining. We further compared 18-month-old WT mice with 13-month-old IL-10KO mice to assess aging-associated cell senescence and inflamation infiltration in both lung and BALF. Moreover, proliferation and apoptosis of alveolar type 2 cells(AT2) were evaluated by FCM, immunofluorescence, TUNEL staining, and TEM analysis. Recombinant IL-10 (rIL-10) was also administered intratracheally to evaluate its therapeutic potential and related mechanism. For the in vitro experiments, 10-week-old naïve pramily lung fibroblasts(PLFs) were treated with the culture medium of 13-month PLFs derived from WT, IL-10KO, or IL-10KO + rIL-10 respectively, and examined the secretion of senescence-associated secretory phenotype (SASP) factors and related pathways.
RESULTS: The aged mice displayed increased susceptibility to fibrosis and decreased IL-10 expression. The 13-month-old IL-10KO mice exhibited significant exacerbation of cell senescence compared to their contemporary WT mice, and even more severe epithelial-mesenchymal transition (EMT) than that of 18 month WT mice. These IL-10 deficient mice showed heightened inflammatory responses and accelerated PF progression. Intratracheal administration of rIL-10 reduced lung CD45 + cell infiltration by 15%, including a 6% reduction in granulocytes and a 10% reduction in macrophages, and increased the proportion of AT2 cells by approximately 8%. Additionally, rIL-10 significantly decreased α-SMA and collagen deposition, and reduced the expression of senescence proteins p16 and p21 by 50% in these mice. In vitro analysis revealed that conditioned media from IL-10 deficient mice promoted SASP secretion and upregulated senescence genes in naïve lung fibroblasts, which was mitigated by rIL-10 treatment. Mechanistically, rIL-10 inhibited TGF-β-Smad2/3 and PTEN/PI3K/AKT/ERK pathways, thereby suppressing senescence and fibrosis-related proteins.
CONCLUSIONS: IL-10 deficiency in aged mice leads to accelerated cell senescence and exacerbated fibrosis, with IL-10KO-PLFs displaying increased SASP secretion. Recombinant IL-10 treatment effectively mitigates these effects, suggesting its potential as a therapeutic target for PF.
NEW MATERIAL:A monoclonal antibody of complement fixation of the group IgG: having a toxic effect specifically upon mouse splenocyte of H-2 haplotype; reacting with Ia antigen shown in B cell of mouse lymphocyte, not reacting with T cell; it and B cell fraction of peripheral lymphocyte obtained from human male and female adult showing 30-70% complement dependent cytotoxicity, it and T cell fraction showing <=5% complement dependent cytotoxicity; among human peripheral mononuclear fraction, T cell obtained by SRBC rossete technique through neuraminidase treatment showing <=3% cytotoxicity, and cell attached to plastic dish showing 75% cytotoxicity. USE:A monoclonal antibody of complement fixation. PROCESS:Mouse ATH(H-2<t2>) is immunized with thymic cell and splenocyte of mouse HTL(H-T<t1>). The spleen of the mouse is taken out, and the splenocyte is fused with a myeloma cell of mouse. The cell is cultivated, the supernatant liquid of the culture containing hybridoma is measured, hybridoma forming the desired antibody is selected, and divided into a colon. The colon are transplanted into a mouse, malignant ascites or serum is obtained from the mouse, to give an antibody.
A composition for use in making dental impressions consists essentially of (1) a diorganopolysiloxane capable of being hardened to the solid elastic state and, as hardening catalyst (2) a tetra-alkylsilicate or an alkylpolysilicate, and (3) a heavy metal alkyl carboxylic acid salt non-toxic under the conditions of use, the hardening catalyst (2) and (3) being used in amount of 9 to 70 parts (by weight) per 100 parts of siloxane (1).  The compositions may also contain fillers, e.g. kaolin, asbestos flour, burnt gypsum, chalk, siliceous chalk, kieselguhr, sulphur, quartz flour, shale flour, titania, zinc, oxide; precipitated chalk and calcium and magnesium silicates; carbon black, graphite, medicinal charcoal, aluminium and copper powders; dextrin, starch, cellulose, cellulose esters and glycollates, alginates, pectins and polyacrylates.  Liquid paraffin and polyvinylether resins, polyethylene and paraffin waxes dissolved in liquid paraffin, polyvinyl pyrrolidone dissolved in glycerol, hexanol or methylcyclohexanone, solvents and plasticizers, e.g. methyl, amyl and benzyl salicylates, benzylbenzoate, benzylphenylacetate, methylcyclohexanol, furfural and benzaldehyde, and wetting or emulsifying agents, e.g. fatty alcoholethylene oxide addition products, may also be added.  The compositions may be coloured with pigments or soluble organic dyes and may contain substances imparting a pleasant odour and taste, e.g. peppermint oil, coumarin and camomile extracts, and also disinfectants, e.g. parachlorometacresol.  In a typical example, a convertible liquid dimethylpolysiloxane, anhydrous burnt gypsum and liquid paraffin were made into a paste and mixed with a liquid mixture of ethylpolysilicate and dibutyltin dilaurate.  The only other catalyst disclosed is a mixture of dibutyltin dilaurate and tetramethylsilicate.ALSO:In making a dental impression, a diorgano-polysiloxane convertible to the solid elastic state is mixed with, as catalyst, a tetraalkyl-silicate or an alkylpolysilicate and a heavy metal carboxylate non-toxic under the conditions of use, the composition so obtained being applied to the patient's mouth and allowed to harden or solidify in the mouth within 10 minutes, the catalyst being used in amount of 9 to 70 parts (by weight) per 100 parts of siloxane.  Inorganic or organic fillers, pigments, dyes, solvents, plasticizers, wetting agents, substances imparting a pleasant odour and taste, and disinfectants, all of which are exemplified, may be added to the compositions.  The ingredients may be mixed in any order, a convenient method being the admixture of equal volumes or lengths of ribbons of different pastes as squeezed out of tubes having identical orifices, the siloxane comprising one paste and the catalyst the other.  In a typical example a convertible liquid dimethylpolysiloxane, anhydrous burnt gypsum and liquid paraffin were made into a paste and mixed with a liquid mixture of ethylpolysilicate and dibutyl tin dilaurate.  The resulting composition was then introduced into a rigid impression mould and an impression taken in the mouth.  Solidification in the mouth took about 3 minutes.
PURPOSE: The objective was to determine the incidence of surgically treated chronic subdural hematoma (cSDH) within six months after head trauma in a consecutive series of head injury patients with a normal initial computed tomography (CT).
METHODS: A total of 1941 adult patients with head injuries who underwent head CT within 48 h after injury and were treated at the Tampere University Hospital's emergency department were retrospectively evaluated from medical records (median age = 59 years, IQR = 39-79 years, males = 58%, patients using antithrombotic medication = 26%). Patients with no signs of acute traumatic intracranial pathology or any type of subdural collection on initial head CT were regarded as CT negative (n = 1573, 81%).
RESULTS: Two (n = 2) of the 1573 CT negative patients received surgical treatment for cSDH. Consequently, the incidence of surgically treated cSDH after a normal initial head CT during a six-month follow-up was 0.13%. Both patients sustained mild traumatic brain injuries initially. One of the two patients was on antithrombotic medication (warfarin) at the time of trauma, hence incidence of surgically treated cSDH among patients with antithrombotic medication in CT negative patients (n = 376, 23.9%) was 0.27%. Additionally, within CT negative patients, one subdural hygroma was operated shortly after trauma.
CONCLUSION: The extremely low incidence of surgically treated cSDH after a normal initial head CT, even in patients on antithrombotic medication, supports the notion that routine follow-up imaging after an initial normal head CT is not indicated to exclude the development of cSDH. Additionally, our findings support the concept of cSDH not being a purely head trauma-related disease.